Matinas BioPharma Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $1.1M | $3.2M | $33,000 |
| Research and development | $85,000 | $11.4M | $14.5M | $16.7M | $14.6M |
| Operating income | -$7.0M | -$24.6M | -$23.8M | -$24.6M | -$24.7M |
| Pretax income | -$10.3M | -$24.3M | -$22.9M | — | — |
| Income tax expense | $7,000 | -$80,000 | — | — | — |
| Net income | -$10.3M | -$24.3M | -$22.9M | -$21.0M | -$23.3M |
| Balance Sheet | |||||
| Cash and equivalents | $4.0M | $7.3M | $4.8M | $6.8M | $21.0M |
| Current assets | $4.1M | $8.0M | $15.5M | $34.5M | $51.0M |
| Total assets | $7.2M | $12.6M | $25.1M | $44.8M | $61.3M |
| Current liabilities | $1.5M | $2.7M | $2.6M | $4.3M | $4.3M |
| Total liabilities | $2.4M | $5.1M | $5.9M | $8.2M | $8.8M |
| Stockholders' equity | $4.8M | $7.6M | $19.2M | $36.6M | $52.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$7.0M | -$15.9M | -$15.3M | -$19.2M | -$15.2M |
| Depreciation and amortization | $32,000 | $365,000 | $385,000 | $337,000 | $244,000 |
| Stock-based compensation | $1.0M | $3.2M | $4.9M | $5.2M | $4.3M |
| Capital expenditure | — | — | $218,000 | $892,000 | $260,000 |
| Free cash flow | — | — | -$15.5M | -$20.0M | -$15.5M |
| Impairments | — | $1.3M | — | $0 | $0 |
Shares outstanding 6.4M · Free float 92.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.